

The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline *CHEK2* c.1100delC families

Maartje A.C. Schreurs^a, Teresa Ramón y Cajal^b, Muriel A. Adank^c, J. Margriet Collée^d, Antoinette Hollestelle^a, Jeroen van Rooij^e, Marjanka K. Schmidt^f, Maartje J. Hooning^{a,*}

^a Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

^b Familial Cancer Clinic, Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain

^c Department of Clinical Genetics, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

^d Department of Clinical Genetics, Erasmus MC Cancer Institute, Rotterdam, the Netherlands

^e Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands

^f Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

ARTICLE INFO

Keywords:

CHEK2 c.1100delC
Breast cancer
Risk prediction

ABSTRACT

To determine the changes in surveillance category by adding a polygenic risk score based on 311 breast cancer (BC)-associated variants (PRS₃₁₁), questionnaire-based risk factors and breast density on personalized BC risk in unaffected women from Dutch *CHEK2* c.1100delC families.

In total, 117 unaffected women (58 heterozygotes and 59 non-carriers) from *CHEK2* families were included. Blood-derived DNA samples were genotyped with the GSAMDv3-array to determine PRS₃₁₁. Lifetime BC risk was calculated in CanRisk, which uses data from the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA). Women, were categorized into three surveillance groups.

The surveillance advice was reclassified in 37.9 % of heterozygotes and 32.2 % of non-carriers after adding PRS₃₁₁. Including questionnaire-based risk factors resulted in an additional change in 20.0 % of heterozygotes and 13.2 % of non-carriers; and a subanalysis showed that adding breast density on top shifted another 17.9 % of heterozygotes and 33.3 % of non-carriers. Overall, the majority of heterozygotes were reclassified to a less intensive surveillance, while non-carriers would require intensified surveillance.

The addition of PRS₃₁₁, questionnaire-based risk factors and breast density to family history resulted in a more personalized BC surveillance advice in *CHEK2*-families, which may lead to more efficient use of surveillance.

1. Introduction

The pathogenic germline *CHEK2* c.1100delC variant is the most prevalent breast cancer (BC) predisposition variant in the Netherlands. It is present in about 1 % of the general Dutch population, increasing to 2.5 % in unselected BC cases and up to 5 % in familial BC cases [1,2]. Depending on family history (FH), the *CHEK2* variant confers a lifetime BC risk (LTBCR, defined as the risk of developing BC from age 20 to 80) of 20–55 % [1–7], compared to the population-based BC risk of 14 % [8]. As a result, relatives of the index case are eligible for genetic counselling. However, over time, discussions have been ongoing to what

extent relatives should be eligible for genetic counselling in families with moderate-risk pathogenic variants. Currently, in the Netherlands, only female first and second degree relatives are eligible for *CHEK2* testing (modified cascade screening) [9]. Based on personal genetic status and FH, an age-specific breast surveillance program is advised [10].

However, there are other known BC risk modifiers, which are mostly currently not yet taken into account during counselling. A more personalized BC risk estimation and surveillance advice would be preferable, especially for young unaffected women. Several comprehensive BC risk prediction models have been developed over the last decade,

* Corresponding author.

E-mail address: m.hooning@erasmusmc.nl (M.J. Hooning).

<https://doi.org/10.1016/j.breast.2023.103611>

Received 25 September 2023; Received in revised form 13 November 2023; Accepted 18 November 2023

Available online 25 November 2023

0960-9776/© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

including the Breast and Ovarian analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) [11], which has been incorporated into the CanRisk prediction tool [12,13]. This model has recently been validated in Dutch women from the general population [14], and includes information on FH [15], genetic testing results, the polygenic risk score (PRS) [16], BMI [17], alcohol consumption [18,19], hormonal factors [20,21], and breast density (BD) [15].

While evidence on the clinical utility of incorporating the PRS in risk prediction of *CHEK2* carriers is still lacking, several studies have shown the added improvement of risk stratification [11,16,22–25]. Firstly, risk effects conferred by *CHEK2* and 77 common variants acted multiplicatively [16] and more recently, two studies including variant status, individual clinical variables and PRS showed meaningful shifts in LTBCR in *CHEK2* carriers regardless of a family history of BC [24,25]. In the familial cancer setting, one study on BC risk prediction of non-*BRCA1/2* Dutch families showed that the addition of PRS₃₁₃ changed clinical management in 58 % of the *CHEK2* carriers [26]. However, a recent study found linkage between two SNPs located on the 22nd chromosome (chr22:29203724:C/T and chr22:29551872:A/G) and the *CHEK2* c.1100delC variant, and therefore using PRS₃₁₃ would result in an overestimation of BC risk in heterozygotes. It is advised to exclude these two SNPs from the PRS and use the PRS₃₁₁ for *CHEK2* families [27].

Within this study, we aimed to investigate the benefit of incorporating PRS₃₁₁, BD and questionnaire-based risk factors (QRFs: including anthropometric information, lifestyle factors, and hormonal factors) in the CanRisk tool one-by-one by evaluating the effect on individual BC risk prediction and changes in screening surveillance advice for unaffected women from *CHEK2* families. Adding this next to FH and *CHEK2* status is expected to result in a more accurate and personalized risk prediction and consequently, more appropriate surveillance advice. We evaluated the impact of using the PRS₃₁₁ versus the PRS₃₁₃ next to FH and *CHEK2* status on BC risk stratification. In addition, we compared risk stratification for first-, second-, and third-degree relatives, contributing to the ongoing discussion on cascade screening for these families.

2. Materials and methods

2.1. Study cohort

We used retrospective cohort data from women participating in the nation-wide Hereditary Breast and Ovarian cancer study Netherlands (HEBON) study. The selected women were counselled at Erasmus MC or AVL-NKI hospital for the *CHEK2* c.1100delC variant. All women had

signed informed consent. The HEBON study has been approved by the Medical Ethics Committee of the Erasmus MC and the Institutional Review Board (IRB) of the AVL-NKI.

We selected 130 women from 93 *CHEK2* families who were unaffected at the time of testing and of whom a DNA sample was available for PRS testing. After excluding six women where a *gBRCA1* PV was found in themselves or their family, two *CHEK2* homozygotes and three women diagnosed with ovarian cancer before testing, 119 women were eligible for this study. After genotyping, two women were excluded as the PRS could not be determined, resulting in a total of 117 women (58 heterozygotes and 59 non-carriers) included in the analyses (Fig. 1).

2.2. Data collection

2.2.1. Questionnaire-based risk factors

Women participating in the HEBON study were asked to complete a detailed questionnaire containing information on risk factors, such as lifestyle factors (alcohol consumption, smoking, physical activity, BMI), hormonal factors (age at menarche and menopause, parity, exogenous hormone use), medical information (e.g. cancer diagnosis, treatment) and preventive strategies (e.g. prophylactic mastectomy). In this study, we will refer to BMI, alcohol consumption and hormonal factors as QRFs. For ten women (four heterozygotes, six non-carriers), no information on any of the addressed QRFs was available.

2.2.2. Pedigrees and medical information

Pedigrees were collected from all participating women. For the LTBCR calculations, FH included all known first-degree to third-degree relatives of genotyped individuals. In addition, missing information from the questionnaire, breast surveillance recommendations given after genetic testing, and BD information (ACR BI-RADS score, category A-D) were extracted from the medical records.

2.2.3. Genotyping

The SNP array platform used was a customized version of the Illumina BeadChip GSA MD, v3 (Illumina GSA Arrays “Infinium iSelect 24x1 HTS Custom BeadChip Kit” – version GOALL). This array was used to determine the 313 BC PRS SNPs, but also the *CHEK2* c.1100delC variant. Samples were processed using the manufacturer’s recommended protocol. 111 of the PRS₃₁₃ variants that could not be directly typed using this array were extracted after imputation against the 1000 genomes reference panel using Minimac. PRS₃₁₃ was standardized to the mean and SD from the population controls included in the total data set from the BCAC study [28], which were −0.424 and 0.611 respectively.




Fig. 1. Flowchart of women excluded from this study.

PRS₃₁₁ was calculated using a mean of -0.096 and SD of 0.609 [27]. The *CHEK2* c.1100delC variant status measured by GSA was compared to the result with the variant status that was retrieved from diagnostic DNA laboratories.

2.3. Statistical analysis

We tested for statistical differences (P -value <0.05) of characteristics between heterozygotes and non-carriers using an ANOVA test for continuous data and Chi-square tests for categorical data. Analyses were performed with STATA (version 17.0) and R (version 4.2.2).

2.3.1. Cumulative risk score calculation

The LTBCR was calculated in the CanRisk tool [version 2.0]. Women were categorized in three risk groups according to the Dutch guidelines [10] by considering risk at general population level if LTBCR was under 20 %, moderate risk if LTBCR was between 20 % and 30 %, and high risk when LTBCR was above 30 %. Also, we evaluated if women would reach a LTBCR of above 50 %, as this threshold is often used in unaffected heterozygote carriers to determine eligibility for preventive surgery. In the LTBCR calculations, we included risk factors stepwise, starting with FH retrieved from the pedigree and the *CHEK2* status. Risk estimation using these two variables was considered the reference, since this is currently used in clinical practice. Our main interest was to address the effect of adding information regarding the PRS₃₁₁, QRFs and BD by considering three different approaches: (1) adding PRS₃₁₁, as this information could be retrieved from the same blood sample and does not require any more information; (2) adding information that could be gathered directly from the individual during genetic testing and counselling, including PRS₃₁₁ and QRFs; and (3) adding all available information, including BD, which was available in our study for 40 heterozygotes and 18 non-carriers. Reasons for missing BD information included (1) not being able to retrieve information from the surveillance hospitals indicated in the questionnaire ($n = 13$); (2) being younger than 35 years at time of data collection and therefore no candidate for mammographic surveillance ($n = 11$); (3) eligible for participating in the Dutch population-based screening program, where we could not retrieve BD information at time of data collection ($n = 14$); and (4) no information on whether women were under BC surveillance or the location of BC surveillance ($n = 21$).

3. Results

3.1. Characteristics of the study population

Table 1 shows the demographic characteristics and risk factors of heterozygotes and non-carriers. Heterozygotes and non-carriers were similar in terms of all established risk factors, except for the use of hormone replacement therapy, which was more common in non-carriers (9.6 % in non-carriers and 0 % in carriers; P -value = 0.02). Overall, over 70 % of the women were a first-degree relative of the index case. Furthermore, the *CHEK2* status as determined by the GSA was always coincident with the *CHEK2* status as determined in the diagnostic setting.

3.2. Stepwise addition of risk factors and BC risk distribution

Fig. 2 shows the LTBCR distribution predicted in CanRisk for heterozygotes and non-carriers, separately. The curves represent the distribution of LTBCR that was calculated. The background of the graphs is shaded indicating the Dutch risk categories for women with a FH of BC [10]. The estimated LTBCR based on FH and *CHEK2* status (green line labelled: FH) ranged from 17.4 % to 51.7 % in heterozygotes, and from 9.2 % to 31.0 % in non-carriers. In addition, the distribution of the estimated LTBCR became wider meaning that we obtained better risk stratification when incorporating the PRS (pink line labelled: FH + PRS).

Table 1

Characteristics of all women (heterozygotes and non-carriers of the familial *CHEK2* c.1100delC variant) included in this study.

Number		Heterozygotes	Non-carriers	P-value	
		58	59		
Center, n (%)	AVL	22 (37.9)	26 (44.1)	0.50	
	Erasmus MC	36 (62.1)	33 (55.9)		
Birth cohort, n (%)	<1960	4 (6.9)	6 (10.1)	0.69	
	1960–1970	16 (27.6)	18 (30.5)		
	1970–1980	22 (37.9)	17 (28.8)		
	1980–1990	11 (19.0)	15 (25.4)		
	>1990	5 (8.6)	3 (5.1)		
Distant relative from the index in pedigree, n (%)	First-degree	42 (72.4)	42 (71.2)	0.98	
	Second-degree	10 (17.2)	11 (18.6)		
	Third-degree	6 (10.3)	6 (10.2)		
Age at time of genetic testing	Mean ± SD	43.7 ± 10.2	45.9 ± 11.3	0.27	
RISK FACTORS					
Height, cm	Mean ± SD	172.7 ± 6.0	171.0 ± 5.4	0.15	
	Unknown	8	12		
Alcohol use, grams per day	None, n (%)	25 (48.1)	26 (50.0)	1.00	
	Mean ± SD	83.7 ± 57.5	96.6 ± 65.5		
Age menarche, years	Unknown	9	7	0.67	
	Mean ± SD	13.0 ± 1.5	12.9 ± 1.3		
Age menopause, years	Unknown	8	8	0.33	
	Premenopausal, n(%)	34 (65.4)	28 (56.0)		0.89
	Mean ± SD	46.6 ± 9.0	46.3 ± 7.6		
Number of children, n (%)	Unknown	7	9	0.96	
	0	8 (15.4)	9 (17.7)		
	1	5 (9.6)	6 (11.8)		
	2	26 (50.0)	25 (49.0)		
	>2	13 (25.0)	11 (21.6)		
Age at first childbirth, years	Unknown	6	8	0.25	
	Mean ± SD	31.6 ± 4.4	30.6 ± 3.8		
	No children	8	9		
Use of oral contraception, n (%)	Unknown	8	5	0.57	
	Never	2 (3.9)	1 (2.0)		
	Ever	50 (96.2)	50 (98.0)		
Use hormone replacement therapy, n(%)	Unknown	6	8	0.02	
	Never	52 (100.0)	46 (90.4)		
	Ever	–	5 (9.6)		
Body mass index, kg/m ²	Unknown	6	7	0.45	
	Mean ± SD	25.5 ± 4.9	26.2 ± 4.0		
Standardized PRS ₃₁₃ , Z-score	Unknown	9	12	0.84	
	Mean	0.479	0.444		
Raw PRS ₃₁₃	SD	1.002	0.851	0.84	
	Mean	−0.132	−0.153		
Standardized PRS ₃₁₁ , Z-score	SD	0.612	0.520	0.13	
	Mean	0.197	0.456		
Raw PRS ₃₁₁	SD	0.988	0.848	0.13	
	Mean	0.028	0.186		
Breast density, n (%)	SD	0.601	0.516	0.87	
	BIRADS A	2 (5.0)	1 (5.6)		
	BIRADS B	15 (37.5)	8 (44.4)		
	BIRADS C	15 (37.5)	7 (38.9)		
	BIRADS D	8 (20.0)	2 (11.1)		
	Unknown	18	41		

PRS₃₁₃ = polygenic breast cancer risk score based on 313 variants; PRS₃₁₁ = alternative polygenic risk score based on 311 BC-associated variants. *Percentages may not add up to 100 % due to rounding.

The addition of QRFs provided an additional improvement in risk distribution (yellow line labelled: FH + QRF + PRS). Based on 40 heterozygotes and 18 non-carriers with BD information, the curves show that the variation in risk is largest when including all available information in the model (purple line labelled: FH + QRF + PRS + BD), especially in the heterozygotes.

3.3. Stepwise addition of risk factors and reclassification of risk category

We compared the LTBCR calculation that is mostly used in current clinical practice (including FH and *CHEK2* status) with a second calculation adding PRS₃₁₁ and a third calculation including all information that could be gathered during genetic testing and counselling (also including PRS₃₁₁ and QRFs) (Table 2). The majority, but not all, of the non-carriers would have been categorized at population risk level, while most of heterozygotes would have been classified as high risk. Adding PRS₃₁₁ resulted in a reclassification of risk category for 37.9 % of the heterozygotes and 32.2 % of the non-carriers compared to the calculation including only FH. Of those who changed risk category, 81.8 % of

the heterozygotes would be recommended less intensive surveillance, while this was true for 42.1 % of the non-carriers. Moreover, adding QRFs resulted in a shift in 38.2 % of the heterozygotes and 41.5 % of the non-carriers compared to the calculation only including FH. The addition of QRFs to the calculation based on FH and PRS₃₁₁ contributed to a shift in 20.0 % of the heterozygotes and 13.2 % of the non-carriers.

Furthermore, we compared the risk group categorization of women from whom we were able to retrieve BD information (Table 3). Adding the QRFs and BD to the calculations based only on FH and PRS₃₁₁, resulted in a shift in 17.5 % of the heterozygotes (85.7 % upscaled), and 22.2 % of the non-carriers (25 % upscaled). The addition of BD alongside FH, PRS₃₁₁ and QRFs contributed to a shift in 17.9 % of the heterozygotes and 33.3 % of the non-carriers.

Finally, we found that some heterozygotes would exceed the 50 % threshold, making them eligible to discuss preventive surgery. In this study, the number of heterozygotes exceeding the 50 % threshold increased after more information was included in the model (Table 2: two heterozygotes for FH alone, three when adding PRS₃₁₁, four when also considering QRFs on top of FH and PRS₃₁₁ and six after adding BD).

3.4. BC risk stratification using PRS₃₁₃ versus PRS₃₁₁

Comparing the model including FH and PRS₃₁₁ with the model




Fig. 2. Distribution of life-time breast cancer risk in *CHEK2* c.1100del carriers (A) and non-carriers (B) calculated using BOADICEA version 6 with stepwise inclusion of risk factors. The background of the graphs are shaded indicating the Dutch lifetime breast cancer risk categories for women [8]: red = population risk ($\leq 20\%$); yellow = moderate risk ($>20\%$ and $<30\%$); blue = high risk ($\geq 30\%$). The vertical purple line indicates the average life-time breast cancer risks for the Dutch population the vertical red line that for *CHEK2* c.1100delC heterozygotes.

FH = family history; QRF = questionnaire-based risk factors; PRS = polygenic risk score based on 311 variants; BD = breast density based on BIRADS

Table 2

Comparison of risk group categorization between the life-time breast cancer risk calculation including family history and mutation status (FH), the calculation also including PRS₃₁₁ (FH + PRS), and the calculation including questionnaire-based risk factors and PRS (FH + QRF + PRS).

Life-time breast cancer risk	FH		FH + PRS		FH + PRS + QRF [†]	
	CHEK2	non-CHEK2	CHEK2	non-CHEK2	CHEK2	non-CHEK2
≤20 %	0	30	5	31	6	31
20–30 %	9	28	15	25	12	22
≥30 %	49	1	38	3	40	6
Of whom >50 %	2	0	3	0	4	0
Total number	58	59	58	59	58	59
Shifts in life-time risk category						
From FH to other, n(%)			20 (34.5)	21 (35.6)	19 (34.5)	24 (45.3)
From FH + PRS to other, n(%)					11 (20.0)	8 (15.1)
Screening category change compared to FH						
Upscaled, n(%)			3 (15.0)	11 (52.4)	4 (21.1)	14 (58.3)
Downscaled, n(%)			17 (85.0)	10 (47.6)	15 (78.9)	10 (41.7)
Screening category change compared to FH + PRS						
Upscaled, n(%)					5 (45.5)	5 (62.5)
Downscaled, n(%)					6 (55.5)	3 (27.5)

Differences in risk groups are shown for heterozygotes and non-carriers separately. The numbers of shifts might be different than expected from the presented data, as individual changes in risk category are not visible within this Table. [†] for three heterozygotes and six non-carriers, relevant QRFs were not available, and therefore only data on FH + PRS were used and by definition they did not change category.

including FH and PRS₃₁₃ showed that the majority of the women did not change risk category. In total, six heterozygotes (10.3 %) and two non-carriers (3.4 %) had an overestimation of risk category when PRS₃₁₃ was used instead of the PRS₃₁₁ (Supplementary Table 1).

3.5. Risk stratification separated by variant status and distant relatives

Based on FH alone, first-, second-, and third-degree relatives were classified in all risk categories. Adding PRS₃₁₁ resulted in reclassifications of risk categories within first-degree relatives (in 14/42 heterozygotes and 14/42 non-carriers), second-degree relatives (in 4/10 heterozygotes and 3/11 non-carriers), and third-degree relatives (in 4/6 heterozygotes and 2/6 non-carriers) (Supplementary Table 2).

4. Discussion

This study showed the potential clinical value of adding known risk factors such as FH, CHEK2 status, PRS₃₁₁, QRFs, and when available, BD to the validated CanRisk tool in personalized BC risk prediction for unaffected heterozygotes and non-carriers of the CHEK2 variant. By incorporating the PRS₃₁₁ along with QRFs, a better stratification of risk and a potential improvement of clinical management was gained. We identified women who had an LTBCR exceeding 50 % and would be eligible for consideration of preventive surgery, which is currently not advised in CHEK2 heterozygotes according to international guidelines [29–31]. Addition of the PRS₃₁₁ and QRFs compared to FH and CHEK2 status alone resulted in the reclassification of risk category for more than one third of the women. The majority of reallocated heterozygotes would be downscaled (76.2 %) and therefore have a later start or lower frequency of screening, whereas most of the non-carriers (59.1 %) would begin surveillance earlier.

Incorporating the PRS into the CanRisk tool had the greatest impact

Table 3

Comparison of risk group categorization between the life-time breast cancer risk calculation including family history and mutation status and PRS₃₁₁ (FH + PRS), the calculation including questionnaire-based risk factors and PRS (FH + QRF + PRS), and the calculation also including breast density (FH + QRF + PRS + BD) in women from whom breast density information was available.

Life-time breast cancer risk	FH + PRS		FH + PRS + QRF [†]		FH + PRS + QRF + BD	
	CHEK2	non-CHEK2	CHEK2	non-CHEK2	CHEK2	non-CHEK2
≤20 %	2	8	3	8	5	9
20–30 %	11	10	9	9	8	8
≥30 %	27	0	28	1	27	1
Of whom >50 %	3	0	4	0	6	0
Total number	40	18	40	18	40	18
Shifts in life-time risk category						
From FH + PRS to other, n(%)			8 (20.5)	5 (27.8)	8 (20.5)	5 (27.8)
From FH + QRF + PRS to other, n(%) [†]					9 (23.1)	5 (27.8)
Screening category change compared to FH + PRS						
Upscaled, n(%)			4 (50.0)	3 (60.0)	5 (62.5)	2 (40.0)
Downscaled, n(%) [*]			4 (50.0)	2 (40.0)	3 (37.5)	3 (60.0)
Screening category change compared to FH + PRS + QRF						
Upscaled, n(%)					3 (33.3)	2 (40.0)
Downscaled, n(%) [*]					6 (66.6)	3 (60.0)

Differences in risk groups are shown for heterozygotes and non-carriers separately. The numbers of shifts might be different than expected from the presented data, as individual changes in risk category are not visible within this Table. [†] for one heterozygotes, relevant QRFs were not available, and therefore only data on FH + PRS were used and by definition they did not change category.

on BC risk prediction, which is in line with previous studies [11,16,23–25,32]. Here, 37.9 % of the heterozygotes and 32.2 % of the non-carriers would have been managed differently if the PRS₃₁₁ had also been included in the model. These percentages are lower than found in another Dutch study, showing that 19 out of the 31 unaffected heterozygotes (58.1 %) would receive different screening advice, of whom 6 (31.6 %) a more intensive surveillance [26]. This might be explained by the use of the PRS₃₁₁ versus PRS₃₁₃, as we showed that the use of PRS₃₁₁ alongside FH did result in lower BC risk category, especially among heterozygotes. As this is the first study conducted using the PRS₃₁₁ in CHEK2 families, we expect to find smaller effects than described in previous studies that used the PRS₃₁₃.

A recent validation of BOADICEA v6 in an independent prospective population-based cohort showed that PRS contributed most to risk stratification followed by BD and finally the QRFs [32], which is in line with our results. Despite the low number of women with information on BD, we found a meaningful extra shift in about one fifth of the women when adding BD on top of the other factors. In addition, although the reported impact of adding QRFs to the model was modest [11,15], their consideration could lead to eventual significant changes in risk prediction, as many are modifiable factors over time. Therefore, special attention should be given while recommending screening for young women under the age of 35 with low PRS and high risk based solely on breast density and nulliparity, as both factors could change over time resulting in a lower BC risk. More research is needed to determine and standardize the best moment for recalculation and the clinical utility of risk-adjusted surveillance recommendations over time.

Currently, discussions in the clinical genetic setting are ongoing on to what extent relatives from CHEK2 families should be tested, as further distant relatives would likely shift more to population-based BC risk.

Although the numbers are small, this is not in line with our results. Similar risk stratifications were found in all distant relatives, also after including other risk factors. On the whole, these results do not support the choice for modified cascade screening in *CHEK2* families.

This study had some limitations. First, changes in lifestyle, reproductive and hormonal information might have occurred from the moment of completing the questionnaire until entering the data into CanRisk. Changes in the use of oral contraceptives, (number) of births, and use of hormone replacement therapy are subject to change during life. However, it is unlikely that this would have great impact on their surveillance advice, especially for women over 50 years for whom changes in surveillance are limited.

Furthermore, BD was only available for 58 women. While evidence is being gathered regarding benefits of implementing PRS in clinical practice, discussion should continue on the importance of considering all evaluable modifiable information, including BD [33,34] and QRFs when offering surveillance, especially with regard to BD due to its nature as a moderate risk factor.

From a clinical point of view, there is a need for personalized risk stratified BC surveillance instead of surveillance programs, which results in less overdiagnoses and lower costs of surveillance, without affecting the quality-adjusted life-years gained and maintaining reduced BC death [35–38]. We showed that adding more information to the model would result in a more stratified BC risk. However, there are some barriers to overcome before implementing this in clinical practice. The addition of PRS₃₁₁ had the most impact on stratifying BC risk. Incorporating this in clinical counselling would be wise in nearby future. Second, even though QRFs vary over time, its inclusion did impact management in a substantial 10–20 % of women. To reduce the burden for genetic counsellors of (manually) entering this information into the model, a public-facing app (MyCanRisk) is currently being developed, allowing people to provide relevant information including QRFs before counselling. This will provide genetic counsellors the information needed for BC risk prediction.

Moreover, the inclusion of BD would be preferred to optimize surveillance recommendations for some women, especially young women who are more likely to have dense breast tissue [15,39]. While BD contributes to large shifts in BC risk categories, we should also keep in mind that BD will decrease over time, e.g. due to (post-)menopausal status, likely resulting in lower BC risk prediction. Therefore, age-dependent risk calculations, or 10-year risk calculations, would be preferable in women with dense breasts and a low risk based on genetic information only.

Overall, this study supports the potential clinical impact of personalized BC risk prediction using CanRisk on individual surveillance advice for women from *CHEK2* families as part of clinical genetic counselling. The BC risk stratification observed in distant relatives, may contribute to ongoing discussions on the extent of cascade genetic screening in *CHEK2* families. Finally, the pros and cons of scaling up and down surveillance programs need to be carefully weighed before implementing in clinical practice.

Ethics approval

This research was reviewed by the Institutional Review Board at the Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute (IRBdm19-043). All data were de-identified prior to analysis.

Funding statement

This research was supported by KWF Kankerbestrijding (project 10758).

Data availability

The data sets generated and/or analyzed during this study are

available to non-commercial parties upon reasonable request from the corresponding author. Only anonymized data will be transferred.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

CRediT authorship contribution statement

All authors contributed to study conception, design, data curation and methodology. Formal analysis were conducted by Maartje A.C. Schreurs, Teresa Ramón y Cajal and Jeroen van Rooij. Funding acquisition was done by Muriel A. Adank, Antoinette Hollestelle, Marjanka K. Schmidt and Maartje J. Hoening. The first draft of the manuscript was written by Maartje A.C. Schreurs and Teresa Ramón y Cajal, supervised by Muriel A. Adank, Marjanka K. Schmidt and Maartje J. Hoening. All authors commented on previous versions of the manuscript, read and approved the final manuscript.

Declaration of competing interest

Authors declare no potential conflict of interest.

Acknowledgements

The authors would like to thank Yvonne Unkel and Kiki Jeanson for their help in the selection and data collection needed for the risk calculations. Also, we would like to thank prof. Douglas F. Easton for his input regarding the PRS₃₁₁ calculations.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.breast.2023.103611>.

References

- [1] Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nat Genet* 2002;31(1):55–9.
- [2] Consortium CBCC-C. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet* 2004;74(6):1175–82.
- [3] Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol* 2008;26(4):542–8.
- [4] Adank MA, Verhoef S, Oldenburg RA, et al. Excess breast cancer risk in first degree relatives of CHEK2*1100delC positive familial breast cancer cases. *Eur J Cancer* 2013;49(8):1993–9.
- [5] Zhang SY, Phelan CM, Zhang P, et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. *Cancer Res* 2008;68(7):2154–7.
- [6] Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. *J Clin Oncol* 2007;25(1):57–63.
- [7] Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. *J Clin Oncol* 2011;29(28):3747–52.
- [8] Netherlands Cancer Registry. www.iknl.nl/borstkankercijfers; 2023.
- [9] Stichting opsporings erfelijke Tumoren. 2023. https://vkgg.stoet.nl/index.php?article_id=23 2023.
- [10] Richtlijndatabase. 2022. https://richtlijndatabase.nl/richtlijn/borstkanker/screening/buiten_het_bob/screening_buiten_het_bevolkingsonderzoek.html.
- [11] Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genet Med* 2019;21(8):1708–18.
- [12] Archer S, Babb de Villiers C, Scheibl F, et al. Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: a multi-methods study. *PLoS ONE [Electronic Resource]* 2020;15(3):e0229999.

- [13] Carver T, Hartley S, Lee A, et al. CanRisk tool-A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. *Cancer Epidemiol Biomarkers Prev* 2021;30(3):469–73.
- [14] Lakeman IMM, Rodriguez-Girondo M, Lee A, et al. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. *Genet Med* 2020;22(11):1803–11.
- [15] Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. *Ann Intern Med* 2012;156(9):635–48.
- [16] Muranen TA, Greco D, Blomqvist C, et al. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genet Med* 2017;19(5):599–603.
- [17] Liu K, Zhang WN, Dai ZM, et al. Association between body mass index and breast cancer risk: evidence based on a dose-response meta-analysis. *Cancer Manag Res* 2018;10:143–50.
- [18] Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA* 2011;306(17):1884–90.
- [19] Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. *Am J Epidemiol* 2007;165(6):667–76.
- [20] Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol* 2012;13(11):1141–51.
- [21] Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive Use and breast cancer: a prospective study of young women. *Cancer Epidemiol Biomarkers* 2010;19(10):2496–502.
- [22] Lakeman IMM, Hilbers FS, Rodriguez-Girondo M, et al. Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families. *J Med Genet* 2019;56(9):581–9.
- [23] Mars N, Widen E, Kerminen S, et al. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. *Nat Commun* 2020;11(1):6383.
- [24] Gao C, Polley EC, Hart SN, et al. Risk of breast cancer among carriers of pathogenic variants in breast cancer predisposition genes varies by polygenic risk score. *J Clin Oncol* 2021;39(23):2564–73.
- [25] Gallagher S, Hughes E, Kurian AW, et al. Comprehensive breast cancer risk assessment for CHEK2 and ATM pathogenic variant carriers incorporating a polygenic risk score and the tyrer-cuzick model. *JCO Precis Oncol* 2021;5.
- [26] Lakeman IMM, Rodriguez-Girondo MDM, Lee A, et al. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases. *J Med Genet* 2023;60(4):327–36.
- [27] Mavaddat N, Ficoella L, Carver T, et al. Incorporating alternative polygenic risk scores into the BOADICEA breast cancer risk prediction model. *Cancer Epidemiol Biomarkers* 2023;32(3):422–7.
- [28] Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. *Am J Hum Genet* 2019;104(1):21–34.
- [29] Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. *J Natl Compr Cancer Netw* 2021;19(1):77–102.
- [30] Sessa C, Balmana J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. *Ann Oncol* 2023;34(1):33–47.
- [31] Robson M. Management of women with breast cancer and pathogenic variants in genes other than BRCA1 or BRCA2. *J Clin Oncol* 2021;39(23):2528–34.
- [32] Yang X, Eriksson M, Czene K, et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. *J Med Genet* 2022;59(12):1196–205.
- [33] Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. *J Natl Cancer Inst* 2011;103(9):744–52.
- [34] Azam S, Eriksson M, Sjolander A, et al. Mammographic density change and risk of breast cancer. *J Natl Cancer Inst* 2020;112(4):391–9.
- [35] Pashayan N, Duffy SW, Chowdhury S, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. *Br J Cancer* 2011;104(10):1656–63.
- [36] Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. *JAMA Oncol* 2018;4(11):1504–10.
- [37] Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. *Ann Intern Med* 2011;155(1):10–20.
- [38] Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. *Breast Cancer Res* 2012;14(1):R25.
- [39] Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of mammographic density and age: implications for breast cancer screening. *AJR Am J Roentgenol* 2012;198(3):W292–5.